Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program ...

After hours: March 11 at 7:51:39 PM EDT Loading Chart for RNA ...

Brook trout may have a genetic trick up their scales when it comes to adapting, with limitations, to heat waves that threaten ...

Fintel reports that on March 12, 2025, BMO Capital initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Outperform recommendation. Analyst Price Forecast Suggests 132.29% Upside As of March ...

Scotiabank began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report issued on Friday morning, ...

Axiomer ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expect ...

One day after being the underbidder on the session topper, agents John Kimmel and Nick Sallusto were able to snag the most ...

Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...

The RNA inhibitor reduces levels of oxidized phospholipids, which are presumed to promote atherosclerosis, by more than 93%.

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...